Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry

dc.contributor.authorNarváez García, Francisco Javier
dc.contributor.authorEAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology)
dc.date.accessioned2018-11-08T12:55:06Z
dc.date.available2018-11-08T12:55:06Z
dc.date.issued2015-07-01
dc.date.updated2018-11-08T12:55:06Z
dc.description.abstractThis article estimates the frequency of cardiovascular (CV) events that occurred after diagnosis in a large Spanish cohort of patients with systemic lupus erythematosus (SLE) and investigates the main risk factors for atherosclerosis. RELESSER is a nationwide multicenter, hospital-based registry of SLE patients. This is a cross-sectional study. Demographic and clinical variables, the presence of traditional risk factors, and CV events were collected. A CV event was defined as a myocardial infarction, angina, stroke, and/or peripheral artery disease. Multiple logistic regression analysis was performed to investigate the possible risk factors for atherosclerosis. From 2011 to 2012, 3658 SLE patients were enrolled. Of these, 374 (10.9%) patients suffered at least a CV event. In 269 (7.4%) patients, the CV events occurred after SLE diagnosis (86.2% women, median [interquartile range] age 54.9 years [43.2-66.1], and SLE duration of 212.0 months [120.8-289.0]). Strokes (5.7%) were the most frequent CV event, followed by ischemic heart disease (3.8%) and peripheral artery disease (2.2%). Multivariate analysis identified age (odds ratio [95% confidence interval], 1.03 [1.02-1.04]), hypertension (1.71 [1.20-2.44]), smoking (1.48 [1.06-2.07]), diabetes (2.2 [1.32-3.74]), dyslipidemia (2.18 [1.54-3.09]), neurolupus (2.42 [1.56-3.75]), valvulopathy (2.44 [1.34-4.26]), serositis (1.54 [1.09-2.18]), antiphospholipid antibodies (1.57 [1.13-2.17]), low complement (1.81 [1.12-2.93]), and azathioprine (1.47 [1.04-2.07]) as risk factors for CV events. We have confirmed that SLE patients suffer a high prevalence of premature CV disease. Both traditional and nontraditional risk factors contribute to this higher prevalence. Although it needs to be verified with future studies, our study also shows-for the first time-an association between diabetes and CV events in SLE patients.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec669962
dc.identifier.issn0025-7974
dc.identifier.pmid26200625
dc.identifier.urihttps://hdl.handle.net/2445/125907
dc.language.isoeng
dc.publisherLippincott, Williams & Wilkins. Wolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1097/MD.0000000000001183
dc.relation.ispartofMedicine, 2015, vol. 94, num. 29, p. e1183
dc.relation.urihttps://doi.org/10.1097/MD.0000000000001183
dc.rightscc-by (c) Narváez García, Francisco Javier et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Ciències Clíniques)
dc.subject.classificationLupus eritematós
dc.subject.classificationInfart de miocardi
dc.subject.classificationMalalties cardiovasculars
dc.subject.classificationArterioesclerosi
dc.subject.otherLupus erythematosus
dc.subject.otherMyocardial infarction
dc.subject.otherCardiovascular diseases
dc.subject.otherArteriosclerosis
dc.titleCardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
669962.pdf
Mida:
231.18 KB
Format:
Adobe Portable Document Format